7:05 am ISIS Pharm announces that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN in children with spinal muscular atrophy; co will receive $9.3 mln in milestone payments – HedgeChatter

7:05 am ISIS Pharm announces that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN in children with spinal muscular atrophy; co will receive $9.3 mln in milestone payments

13 Feb

7:05 am ISIS Pharm announces that the first child in the 12 mg group was dosed in the ongoing Phase 2 study evaluating ISIS-SMN in children with spinal muscular atrophy; co will receive $9.3 mln in milestone payments

Bystocknews ISIS, stock Comments Off

View todays social media effects on ISIS

View the latest stocks trending across Twitter. Click to view dashboard

See who Isis is hiring next, click here to view

Author